deferiprone has been researched along with Idiopathic Parkinson Disease in 9 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Wilkinson, KA | 1 |
| Guo, C | 1 |
| Devos, D | 6 |
| Labreuche, J | 3 |
| Rascol, O | 3 |
| Corvol, JC | 4 |
| Duhamel, A | 4 |
| Guyon Delannoy, P | 3 |
| Poewe, W | 3 |
| Compta, Y | 3 |
| Pavese, N | 3 |
| Růžička, E | 3 |
| Dušek, P | 3 |
| Post, B | 3 |
| Bloem, BR | 3 |
| Berg, D | 3 |
| Maetzler, W | 3 |
| Otto, M | 3 |
| Habert, MO | 3 |
| Lehericy, S | 3 |
| Ferreira, J | 3 |
| Dodel, R | 3 |
| Tranchant, C | 3 |
| Eusebio, A | 3 |
| Thobois, S | 3 |
| Marques, AR | 3 |
| Meissner, WG | 3 |
| Ory-Magne, F | 3 |
| Walter, U | 3 |
| de Bie, RMA | 3 |
| Gago, M | 3 |
| Vilas, D | 3 |
| Kulisevsky, J | 3 |
| Januario, C | 3 |
| Coelho, MVS | 3 |
| Behnke, S | 3 |
| Worth, P | 3 |
| Seppi, K | 3 |
| Ouk, T | 3 |
| Potey, C | 3 |
| Leclercq, C | 3 |
| Viard, R | 3 |
| Kuchcinski, G | 3 |
| Lopes, R | 3 |
| Pruvo, JP | 3 |
| Pigny, P | 3 |
| Garçon, G | 5 |
| Simonin, O | 3 |
| Carpentier, J | 3 |
| Rolland, AS | 4 |
| Nyholm, D | 3 |
| Scherfler, C | 3 |
| Mangin, JF | 3 |
| Chupin, M | 3 |
| Bordet, R | 5 |
| Dexter, DT | 4 |
| Fradette, C | 3 |
| Spino, M | 4 |
| Tricta, F | 4 |
| Ayton, S | 4 |
| Bush, AI | 4 |
| Devedjian, JC | 6 |
| Duce, JA | 5 |
| Cabantchik, I | 3 |
| Defebvre, L | 5 |
| Deplanque, D | 3 |
| Moreau, C | 6 |
| Cabantchik, ZI | 2 |
| Danel, V | 1 |
| Mahoney-Sanchez, L | 1 |
| Bouchaoui, H | 1 |
| Gouel, F | 1 |
| Zhang, Q | 1 |
| Feng, S | 1 |
| Zhao, Y | 1 |
| Jin, B | 1 |
| Peng, R | 1 |
| Martin-Bastida, A | 1 |
| Ward, RJ | 1 |
| Newbould, R | 1 |
| Piccini, P | 1 |
| Sharp, D | 1 |
| Kabba, C | 1 |
| Patel, MC | 1 |
| Connelly, J | 1 |
| Crichton, RR | 1 |
| Sun, Y | 1 |
| Pham, AN | 1 |
| Waite, TD | 1 |
| Lei, P | 1 |
| Wong, BX | 1 |
| Sedjahtera, A | 1 |
| Adlard, PA | 1 |
| Finkelstein, DI | 1 |
| Kluza, J | 1 |
| Petrault, M | 1 |
| Laloux, C | 1 |
| Jonneaux, A | 1 |
| Ryckewaert, G | 1 |
| Rouaix, N | 1 |
| Jissendi, P | 1 |
| Dujardin, K | 1 |
| Auger, F | 1 |
| Ravasi, L | 1 |
| Hopes, L | 1 |
| Grolez, G | 2 |
| Firdaus, W | 1 |
| Sablonnière, B | 2 |
| Strubi-Vuillaume, I | 1 |
| Zahr, N | 1 |
| Destée, A | 1 |
| Pöltl, D | 1 |
| Leist, M | 1 |
| Rose, C | 1 |
| Marchetti, P | 1 |
| Meguig, S | 1 |
| Gelé, P | 1 |
| Delmaire, C | 1 |
| Cabantchik, IZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease[NCT01539837] | Phase 2 | 22 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease[NCT00943748] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease, modify regional brain mineralization (iron concentration) as assessed with T2* MRI in PD patients in the dentate nucleus. In previous animal studies, Deferiprone treatment reduced dentate nucleus iron content, as assessed by MRI. An increase in the T2*MRI value represents an increase in mineralization. (NCT01539837)
Timeframe: 6 months
| Intervention | ms (Mean) |
|---|---|
| Placebo | 30.74 |
| Deferiprone 20mg | 30.59 |
| Deferiprone 30mg | 29.86 |
To assess whether there were any serious adverse events in 6-month treatment with Deferiprone. (NCT01539837)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Deferiprone 20mg | 0 |
| Deferiprone 30mg | 0 |
1 review available for deferiprone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Chelation Therapy; Deferiprone; Humans; Iron; Iron Chelating | 2020 |
4 trials available for deferiprone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
Topics: Aged; Brain; Brain Chemistry; Deferiprone; Double-Blind Method; Female; Humans; Inflammation; Iron; | 2017 |
Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Topics: Animals; Cell Line; Combined Modality Therapy; Deferiprone; Disease Models, Animal; Double-Blind Met | 2014 |
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
Topics: Aged; Ceruloplasmin; Chelation Therapy; Clinical Protocols; Deferiprone; Female; Humans; Iron; Iron | 2015 |
4 other studies available for deferiprone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Iron chelation promotes mitophagy through SENP3-mediated deSUMOylation of FIS1.
Topics: Autophagy; Cysteine Endopeptidases; Deferiprone; Humans; Iron Chelating Agents; Membrane Proteins; M | 2022 |
Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.
Topics: Animals; Calcium; Cell Survival; Deferiprone; Drug Design; Hydrogen Peroxide; Iron Chelating Agents; | 2021 |
Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
Topics: Animals; Deferiprone; Disease Models, Animal; Dopamine; Iron; Iron Chelating Agents; Oxidative Stres | 2018 |
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Ceruloplasmin; De | 2013 |